Based on the SMILES representation CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C, the molecule has a drug half life time in humans after IV administration of 0.500 hours.
Based on the {SMILES__description} {#representation |!}{SMILES#}, the molecule has a {half_life_duration__names__noun} of {half_life_duration#} {half_life_duration__units}.
[2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate